DE69840586D1 - Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien - Google Patents

Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien

Info

Publication number
DE69840586D1
DE69840586D1 DE69840586T DE69840586T DE69840586D1 DE 69840586 D1 DE69840586 D1 DE 69840586D1 DE 69840586 T DE69840586 T DE 69840586T DE 69840586 T DE69840586 T DE 69840586T DE 69840586 D1 DE69840586 D1 DE 69840586D1
Authority
DE
Germany
Prior art keywords
cyclosporine
substitution
disclosed
derivatives
cyclosporine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69840586T
Other languages
English (en)
Inventor
S Selveraj Naicker
Robert T Foster
Randall W Yatscoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isotechnika Inc
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Application granted granted Critical
Publication of DE69840586D1 publication Critical patent/DE69840586D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69840586T 1997-10-08 1998-10-08 Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien Expired - Fee Related DE69840586D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6136097P 1997-10-08 1997-10-08

Publications (1)

Publication Number Publication Date
DE69840586D1 true DE69840586D1 (de) 2009-04-02

Family

ID=22035297

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69840586T Expired - Fee Related DE69840586D1 (de) 1997-10-08 1998-10-08 Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
DE69832984T Expired - Lifetime DE69832984T2 (de) 1997-10-08 1998-10-08 DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69832984T Expired - Lifetime DE69832984T2 (de) 1997-10-08 1998-10-08 DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN

Country Status (14)

Country Link
US (3) US6613739B1 (de)
EP (1) EP0991660B8 (de)
JP (6) JP4261049B2 (de)
KR (1) KR100585348B1 (de)
AT (2) ATE423130T1 (de)
AU (1) AU750245B2 (de)
BR (1) BR9811716A (de)
CA (1) CA2298572C (de)
DE (2) DE69840586D1 (de)
DK (1) DK0991660T3 (de)
ES (1) ES2256959T3 (de)
NO (1) NO324042B1 (de)
NZ (1) NZ502362A (de)
WO (1) WO1999018120A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP2062583B1 (de) * 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutische Anwendungen proapoptotischer Benzodiazepine
US6784156B2 (en) * 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US20030087813A1 (en) 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
CN100334106C (zh) * 2001-10-19 2007-08-29 伊索泰克尼卡股份有限公司 环孢菌素类似物的合成
ES2310604T3 (es) * 2001-10-19 2009-01-16 Isotechnika, Inc. Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
DE60233150D1 (de) * 2001-10-19 2009-09-10 Isotechnika Inc Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
US20040110666A1 (en) * 2002-12-04 2004-06-10 Or Yat Sun Cyclosporins for the treatment of immune disorders
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US20040266669A1 (en) * 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1729814A2 (de) * 2004-04-01 2006-12-13 Cardiome Pharma Corp. Pegylierte ionenkanalmodulatoren
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
WO2006014872A2 (en) * 2004-07-29 2006-02-09 Amr Technology, Inc. Novel processes for stereoselective synthesis of trans isatx 247
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
EP1828099B1 (de) 2004-11-18 2020-01-22 Correvio International Sàrl Syntheseverfahren für aminocyclohexyl-ether-verbindungen
TW200635954A (en) * 2004-12-17 2006-10-16 Isotechnika Inc Metabolites of cyclosporin analogs
WO2006074358A1 (en) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP2180323B1 (de) * 2005-04-06 2012-02-01 Abbott Laboratories Verfahren zur Messung immunsuppressiver Tacrolimus-, Sirolimus- und Cyclosporin-A-Komplexe in einer Blutprobe
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
BRPI0612138B8 (pt) 2005-06-15 2021-05-25 Cardiome Pharma Corp compostos éter aminocicloexílicos e método para fazer os mesmos
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
DK1954669T3 (en) 2005-12-01 2015-10-12 Auspex Pharmaceuticals Inc SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8155649B2 (en) * 2006-05-12 2012-04-10 Shared Spectrum Company Method and system for classifying communication signals in a dynamic spectrum access system
WO2007146167A1 (en) 2006-06-09 2007-12-21 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
JP5383513B2 (ja) 2007-03-09 2014-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物ならびに方法
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
WO2009018424A2 (en) 2007-08-01 2009-02-05 Emory University Methods for determination of protein phosphatase activity, and uses in predicting therapeutic outcomes
WO2009036175A2 (en) 2007-09-14 2009-03-19 The Regents Of The University Of Michigan F1f0-atpase inhibitors and related methods
RU2010122902A (ru) 2007-11-06 2011-12-20 Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) Бензодиапениноновые соединения, применимые в лечении кожных состояний
DK2268604T3 (en) 2008-03-14 2017-03-27 Retrotope Inc CANCER THERAPIES BY USING ISOTO-SUBSTITUTED LYSIN
MX2011000637A (es) * 2008-07-15 2011-05-02 Theracos Inc Derivados deuretados de bencilbenceno y metodos de uso.
NZ590517A (en) * 2008-07-30 2012-12-21 Isotechnika Pharma Inc Nonimmunosuppressive cyclosporine analogue molecules
WO2010027448A1 (en) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
JP2012502038A (ja) * 2008-09-03 2012-01-26 テバ ファーマシューティカル インダストリーズ リミティド 免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター
EP2352724B1 (de) 2008-09-11 2015-04-22 The Regents of the University of Michigan Arylguanidine-f1f0-aptase inhibitoren und deren therapeutischen verwendung
EP2340242A4 (de) * 2008-10-22 2012-04-04 Acucela Inc Verbindungen zur behandlung von augenerkrankungen und -leiden
EP2391376A4 (de) 2009-01-30 2012-08-01 Enanta Pharm Inc Cyclosporin-analoga zur prävention oder behandlung von hepatitis-c-infektionen
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
EP2470020A4 (de) 2009-09-18 2013-03-13 Univ Michigan Benzodiazepinonverbindungen und behandlungsverfahren damit
EP2493296B1 (de) 2009-10-30 2019-01-09 Retrotope, Inc. Minderung von oxidativen stresserkrankungen mit pufa-derivaten
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
CN107496902B (zh) 2010-12-15 2022-01-18 康卓维尔制药公司 在氨基酸1和3位修改的环孢菌素类似分子
WO2012145426A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
EP2701697B1 (de) 2011-04-26 2020-03-25 Retrotope, Inc. Oxidative netzhauterkrankungen
ES2859753T3 (es) 2011-04-26 2021-10-04 Retrotope Inc Trastornos que implican la oxidación de PUFA
WO2012148927A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
CN106479990B (zh) 2011-11-18 2020-09-18 科德克希思公司 用于制备羟基取代的氨基甲酸酯的生物催化剂
EP2841098A4 (de) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanopartikel zur behandlung von allergien
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
JP2016516754A (ja) 2013-04-03 2016-06-09 アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｌｅｒｔｅｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 新規のナノ粒子組成物
MX2016002458A (es) 2013-08-26 2016-08-08 Enanta Pharm Inc Análogos novedosos de ciclosporina para prevenir o tratar la infección por hepatitis c.
EP3094314B1 (de) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Gezielte nanoträger zur verabreichung von immunsuppressiva
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
KR102643910B1 (ko) 2015-11-23 2024-03-06 레트로토프 인코포레이티드 1,4-다이엔 시스템에 대한 부위 특이적인 동위원소 표지법
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
EP3713571A4 (de) * 2018-01-12 2021-08-25 ENB Therapeutics, Inc. Deuterierte verbindungen, zusammensetzungen und verfahren zur behandlung von mit etbr-aktivierung assoziiertem krebs
US11584779B2 (en) 2018-10-19 2023-02-21 Teva Pharmaceuticals International Gmbh Solid state forms of voclosporin
WO2021168311A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
BR112022018929A2 (pt) * 2020-03-26 2022-12-06 Farsight Medical Tech Shanghai Co Ltd Inibidores da ciclofilina e seus usos
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
EP4201952A1 (de) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Verfahren zur kontrollierten synthese von voclosporin
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
WO2025119925A1 (en) 2023-12-05 2025-06-12 Medichem, S.A. Process for preparing voclosporin

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (de) 1975-11-04 1979-12-28 Sandoz Ag
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en) 1979-03-12 1980-05-06 Merck & Co., Inc. Antibiotic A43F
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
AU548156B2 (en) 1980-02-14 1985-11-28 Novartis Ag Cyclo sporin
FR2487198A1 (fr) 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4384996A (en) 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NZ212051A (en) 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8422253D0 (en) 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
EP0194972B1 (de) 1985-03-11 1992-07-29 Sandoz Ag Cyclosporine
US4765980A (en) 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4764503A (en) 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
HU205861B (en) 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
US5239057A (en) 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US5427960A (en) 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
EP0283801A3 (de) * 1987-03-27 1990-05-30 Abbott Laboratories Fluoreszenz-Polarisations-Test für Cyclosporin A und Metaboliten und verwandte Immunogene und Antikörper
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
DE3884470T2 (de) * 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
ATE110784T1 (de) 1987-06-19 1994-09-15 Sandoz Ag Zyklische peptolide.
DE3888357T2 (de) 1987-06-22 1994-09-15 Merck & Co Inc Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
GB8717299D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Peptides
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
DE3851152T2 (de) 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US5236899A (en) 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5013719A (en) 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
WO1990006763A1 (en) 1988-12-05 1990-06-28 The Trustees Of Columbia University In The City Of New York Novel derivatives of cyclosporine a, antibodies directed thereto and uses thereof
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en) 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
DE69116034T2 (de) 1990-08-15 1996-06-20 Abbott Lab Immunotestreagenzien und Verfahren zur Bestimmung von Cyclosporin
ATE148469T1 (de) 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5115859A (en) 1990-12-21 1992-05-26 United Technologies Corporation Regenerable non-venting cooler for protective suit
ATE127528T1 (de) 1991-04-06 1995-09-15 Dresden Arzneimittel Verfahren zur fermentativen herstellung und isolierung von cyclosporin a sowie neue cyclosporin- bildende stämme.
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
HU213553B (en) 1992-05-25 1997-07-28 Biogal Gyogyszergyar Process for isolating of cyclosporin-a
FI92334C (fi) 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
JPH09500103A (ja) 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド シクロヘキサペプチジルアミノアルキルエーテル
CA2186371A1 (en) * 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US5639852A (en) 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US5709797A (en) 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins
US5747330A (en) 1996-06-05 1998-05-05 Poli Industria Chimica Antibiotic producing microbe

Also Published As

Publication number Publication date
JP2008222724A (ja) 2008-09-25
BR9811716A (pt) 2000-07-18
JP2004143168A (ja) 2004-05-20
US6605593B1 (en) 2003-08-12
EP0991660A1 (de) 2000-04-12
DE69832984T2 (de) 2006-09-21
AU750245B2 (en) 2002-07-11
CA2298572C (en) 2002-04-09
JP2001519355A (ja) 2001-10-23
JP2007119489A (ja) 2007-05-17
EP0991660B8 (de) 2006-04-05
JP4261049B2 (ja) 2009-04-30
US20020132763A1 (en) 2002-09-19
NO324042B1 (no) 2007-07-30
ATE423130T1 (de) 2009-03-15
CA2298572A1 (en) 1999-04-15
DE69832984D1 (de) 2006-02-02
KR20010030978A (ko) 2001-04-16
US6613739B1 (en) 2003-09-02
ATE314388T1 (de) 2006-01-15
NZ502362A (en) 2001-05-25
KR100585348B1 (ko) 2006-06-01
NO20001020L (no) 2000-02-29
ES2256959T3 (es) 2006-07-16
NO20001020D0 (no) 2000-02-29
JP2008222725A (ja) 2008-09-25
JP2005343904A (ja) 2005-12-15
DK0991660T3 (da) 2006-02-13
WO1999018120A1 (en) 1999-04-15
HK1026432A1 (en) 2000-12-15
EP0991660B1 (de) 2005-12-28
AU9454298A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
DE69840586D1 (de) Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
Kruger et al. Electron capture dissociation of multiply charged peptide cations
Tomer et al. Fast-atom bombardment combined with tandem mass spectrometry for the determination of cyclic peptides
Kenny et al. Fragmentation studies of peptides: the formation of y ions
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
CA2235138A1 (en) Reverse-turn mimetics and methods relating thereto
HUP0002381A1 (hu) Apolipoprotein A-1 agonista hatású peptidszármazékok, ezek lipidekkel alkotott komplexei, valamint ezeket tartalmazó gyógyászati készítmények
DE69912952D1 (en) Cyclosporine
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
PL297902A1 (en) Novel cyclosporines and method of obtaining them
WO1995011309A3 (en) A novel nuclear mitotic phosphoprotein: mitosin
UA42819C2 (uk) Ін`єкційний та інфузійний розчин, що містить енрофлокcацин
NZ336793A (en) Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture
BR0312889A (pt) Polipeptìdeo t20 peguilado
PT1107981E (pt) Sintese de analogos peptidicos ciclicos de anel modificado
Ali et al. Solid-phase total synthesis of cyclic decapeptide phakellistatin 12
WO1997044354A3 (en) Synthesis of soluble beta-sheet forming peptides
CA2511888A1 (en) Deuterated cyclosporin analogs and their use as immunomodulating agents
CA2372639A1 (en) Deuterated cyclosporine analogs and their use as immunomodulating agents
EP0438600A4 (en) Enzymes which participate in c-terminal amidation, and production and use thereof
TR200002293T2 (tr) Farmasötik bileşimler.
CA2137037A1 (en) Fluorinated Diazabicycloalkane Derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee